Galaxy Surfactants Q2 FY27 consolidated revenue Rs 1,810.41 cr; PAT Rs 119.75 cr

Galaxy Surfactants Q2 FY27 consolidated revenue Rs 1,810.41 cr; PAT Rs 119.75 cr

Galaxy Surfactants’ consolidated revenue from operations was Rs 1,810.41 cr and profit after tax Rs 119.75 cr for Q2 FY27, both higher than a year earlier.

Galaxy Surfactants Ltd
Galaxy Surfactants LtdReviewed and published by · How we report
2 min read
galaxy surfactantsq2 fy27 resultsearningsconsolidatedchemicals
ShareWhatsAppXLinkedIn

Key takeaways

  • Revenue from operations for Q2 FY27 was Rs 1,810.41 cr vs Rs 1,326.17 cr a year earlier.
  • Total income for Q2 FY27 was Rs 1,816.77 cr vs Rs 1,331.96 cr in Q2 FY26.
  • Profit after tax for Q2 FY27 was Rs 119.75 cr vs Rs 66.49 cr a year earlier.
  • Total expenses for Q2 FY27 were Rs 1,665.56 cr vs Rs 1,252.76 cr in Q2 FY26.
  • Basic EPS for Q2 FY27 was Rs 33.78* vs Rs 18.75* in Q2 FY26 (*not annualised).

Q2 FY27 · consolidated

MetricSep 2026Sep 2025Change
RevenueRs 1,810.41 crRs 1,326.17 cr+36.5%
PATRs 119.75 crRs 66.49 cr+80.1%

As reported in the filing. Figures are transcribed, not computed.

What the numbers show

  • Net margin was 6.61% of revenue, up 160 bps from 5.01%.
  • Revenue rose 36.5% while total expenses rose 33.0%.
  • Cost of materials accounted for Rs 313.65 cr of the Rs 412.80 cr rise in total expenses (75%).
  • Cost of materials took 73.4% of revenue, against 76.6% a year earlier.

• Basis: Consolidated statement of unaudited financial results for the quarter ended 30th September, 2026, with prior comparable quarter ended 30th September, 2025, as per the statement of financial results.

• Revenue from operations
• Current (30th September, 2026): Rs 1,810.41 cr
• Prior (30th September, 2025): Rs 1,326.17 cr

• Total income (Revenue from operations + Other income)
• Current: Rs 1,816.77 cr
• Prior: Rs 1,331.96 cr

• Total expenses
• Current: Rs 1,665.56 cr
• Prior: Rs 1,252.76 cr

• Cost of materials consumed
• Current: Rs 1,328.99 cr
• Prior: Rs 1,015.34 cr

• Purchases of stock-in-trade
• Current: Rs 15.34 cr
• Prior: Rs 22.95 cr

• Changes in inventories of finished goods (including stock-in-trade) and work-in-progress
• Current: Rs (32.65) cr
• Prior: Rs (37.03) cr

• Employee benefits expense
• Current: Rs 104.50 cr
• Prior: Rs 80.52 cr

• Finance costs
• Current: Rs 9.95 cr
• Prior: Rs 7.28 cr

• Depreciation, amortisation and impairment expenses
• Current: Rs 34.72 cr
• Prior: Rs 29.81 cr

• Other expenses
• Current: Rs 204.71 cr
• Prior: Rs 133.89 cr

• Profit before tax (PBT)
• Current: Rs 151.21 cr
• Prior: Rs 79.20 cr

• Profit after tax (PAT)
• Current: Rs 119.75 cr
• Prior: Rs 66.49 cr

• Earnings per share (EPS), basic (Face value Rs 10 per share)
• Current: Rs 33.78*
• Prior: Rs 18.75*
(*Not annualised, as disclosed in the statement of financial results.)

For Q2 FY27 (quarter ended 30th September, 2026), the consolidated statement of financial results shows higher revenue from operations and total income compared with the corresponding quarter ended 30th September, 2025. Total expenses also increased over the same period, led by higher cost of materials consumed, employee benefits expense and other expenses.

Profit before tax and profit after tax for the quarter are higher than in the corresponding prior-year quarter, as per the profit before tax and profit after tax lines in the statement of financial results. Basic and diluted earnings per share for the quarter, on a face value of Rs 10 per share, are also higher year-on-year, based on the EPS figures disclosed in the same table.

Track Galaxy Surfactants Ltd

Cruxal reads every Galaxy Surfactants Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.

Get every filing that moves a stock

One email before the open, with the day's filings that actually shifted a price — the number, the source document and what the market did with it. Free, and you can unsubscribe from any issue.

Cruxal publishes market coverage for information only. Nothing here is investment advice.